84. サルコイドーシス Sarcoidosis Clinical trials / Disease details
臨床試験数 : 149 / 薬物数 : 227 - (DrugBank : 81) / 標的遺伝子数 : 82 - 標的パスウェイ数 : 167
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCTs011210048 | 05/11/2021 | 05/11/2021 | Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial | Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial - CHASM CS- RCT | Cardiac Sarcoidosis Cardiac Sarcoidosis | Subjects meeting the study inclusion/exclusion criteria will be randomized equally to receive either: 1. Prednisone 0.5 mg kg/day for 6-months (MAX dose 30 mg per day) or 2. Methotrexate 15-20 mg po, sc, or IM once a week for 6-months + Folic Acid 2 mg OD for 6 months + Prednisone 20 mg day for 1 month, then 10 mg OD for 1 month, then 5 mg OD for one month then STOP | Toshiyuki Nagai | NULL | Pending | >= 18age old | Not applicable | Both | 194 | Phase 3 | Canada;United States;United Kingdom;Japan |
| 2 | JPRN-jRCTs041180111 | 16/12/2016 | 19/03/2019 | Estimated by FDG PET/CT in Myocardial Sarcoidosis | Optimal Medical Therapy Estimated by FDG PET/CT in Myocardial Sarcoidosis - OMT-CS study | Cardiac sarcoidosis Cardiac sarcoidosis | After using PSL for 6 months, patients were classified by decreasing rate of TLG. If TLG is decreasing over 70%, PSL was prescribed 5mg/day for more 6 months. If TLG is decreasing under 70%, arm A: PSL was prescribed 30mg/day and diminishing PSL 5mg per month for more 6 months arm B: MTX (6mg/week) and folic acid (5mg/week) was prescribed for more 6 months | Murohara Toyoaki | NULL | Complete | >= 20age old | Not applicable | Both | 50 | Phase 3 | Japan |